Oxaprozin-d5

• Description:

  Oxaprozin-d5 is deuterium labeled Oxaprozin. Oxaprozin is an inhibitor of both COX-1 and COX-2 with IC50s of 2.2 μM and 36 μM for human platelet COX-1 and IL-1-stimulated human synovial cell COX-2, respectively. Oxaprozin also inhibits the activation of NF-κB.

• Product Name Alternative:

  Oxaprozinum-d5; Wy21743-d5

• UNSPSC:

  12352005

• Target:

  COX; Isotope-Labeled Compounds; NF-κB

• Type:

  Isotope-Labeled Compounds

• Related Pathways:

  Immunology/Inflammation; NF-κB; Others

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Inflammation/Immunology; Cancer

• Solubility:

  10 mM in DMSO

• Smiles:

  O=C(O)CCC1=NC(C2=CC=CC=C2)=C(C3=C([2H])C([2H])=C([2H])C([2H])=C3[2H])O1

• Molecular Formula:

  C18H10D5NO3

• Molecular Weight:

  298.35

• References & Citations:

  [1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216.|[2]Montecucco F, et al. Oxaprozin-induced apoptosis on CD40 ligand-treated human primary monocytes is associated with the modulation of defined intracellular pathways. J Biomed Biotechnol. 2009;2009:478785.|[3]Ottonello L, et al. Delayed apoptosis of human monocytes exposed to immune complexes is reversed byoxaprozin: role of the Akt/IkappaB kinase/nuclear factor kappaB pathway. Br J Pharmacol. 2009 May;157 (2) :294-306.

• Shipping Conditions:

  Room temperature

• Scientific Category:

  Isotope-Labeled Compounds

• Clinical Information:

  No Development Reported

• CAS Number:

  [2933758-40-6]